首页> 外文期刊>Liver international : >Manganese superoxide dismutase activity and incidence of hepatocellular carcinoma in patients with Child-Pugh class A liver cirrhosis: a 7-year follow-up study.
【24h】

Manganese superoxide dismutase activity and incidence of hepatocellular carcinoma in patients with Child-Pugh class A liver cirrhosis: a 7-year follow-up study.

机译:Child-Pugh A级肝硬化患者中锰超氧化物歧化酶活性和肝细胞癌的发生率:7年的随访研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Aims: To evaluate possible modifications in the manganese superoxide dismutase (MnSOD) activity during neoplastic transformation of a cirrhotic liver and to find out whether its assessment may have predictive value to identify cirrhotic patients at a higher risk of hepatocellular carcinoma (HCC). Methods: Seventy-one consecutive subjects with Child-Pugh class A liver cirrhosis were recruited. At the time of enrolment, HCC was diagnosed in 20 cirrhotic patients. The 51 cirrhotic patients without HCC were followed up for the occurrence of tumour by 6-monthly screening for 7 years. During follow-up, 16 patients developed HCC. Seventy healthy subjects formed the control group. MnSOD activity was assayed spectrophotometrically. Results: Serum MnSOD activity was significantly lower in 70 healthy subjects compared with 51 cirrhotic patients and 20 cirrhotic patients with HCC. Cirrhotic patients who developed HCC during follow-up showed significantly higher values of MnSOD activity than HCC-free patients. The best cut-off of MnSOD activity was 0.40 U/ml. At this cut-off, chi(2) analysis revealed that MnSOD activity was significantly different between the HCC-free cirrhotic patients and cirrhotic patients who developed HCC. Conclusion: The present findings suggest that during neoplastic transformation of cirrhotic liver, an increase in MnSOD activity may occur already during the precancerous phase, making this enzyme a probable malignancy-associated parameter.
机译:目的:评估肝硬化肿瘤转化过程中锰超氧化物歧化酶(MnSOD)活性的可能改变,并查明其评估是否具有预测价值,以鉴定肝癌(HCC)风险较高的肝硬化患者。方法:招募了连续的Child-Pugh A级肝硬化患者71例。在入组时,有20名肝硬化患者被诊断出HCC。对51例无HCC的肝硬化患者,每6个月进行一次随访,随访7年。在随访期间,有16例患者发生了HCC。七十名健康受试者组成对照组。 MnSOD活性用分光光度法测定。结果:70例健康受试者的血清MnSOD活性显着低于51例肝硬化患者和20例HCC肝硬化患者。在随访期间发生HCC的肝硬化患者的MnSOD活性值明显高于无HCC的患者。 MnSOD活性的最佳截止值为0.40 U / ml。在此临界值上,chi(2)分析显示,在无HCC的肝硬化患者和发生HCC的肝硬化患者之间,MnSOD活性显着不同。结论:目前的发现表明,在肝硬化的肿瘤转化过程中,MnSOD活性可能在癌前期已经出现增加,从而使该酶成为可能的恶性肿瘤相关参数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号